ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the pioneer in tubeless insulin pump technology with its Omnipod brand, is thrilled to announce the full commercial launch of Omnipod 5 in the United Kingdom and the Netherlands. Omnipod 5, the next-generation insulin management system, is designed for individuals aged two years and older with type 1 diabetes. With its compatibility with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, this innovative device aims to transform the lives of diabetes patients in these countries.
Omnipod 5 marks a significant milestone in the management of diabetes, as it is the first and only tubeless automated insulin delivery system that integrates the Dexcom G6 and Abbott FreeStyle Libre 2 Plus CGM sensors. This compatibility allows users to have real-time access to their glucose levels, enabling them to make informed decisions about insulin dosing and overall diabetes management. The integration of these sensors adds convenience and ease of use, empowering individuals to take control of their health by making more informed choices.
By harnessing the combined power of these leading CGM technologies, Omnipod 5 offers an unparalleled level of accuracy and reliability in monitoring glucose levels. The system provides customizable alerts and automatic insulin delivery adjustments, ensuring precise and smart insulin dosing. With the freedom from tubes and wires, users can enjoy a more seamless and comfortable insulin delivery experience, enhancing their quality of life.
The launch of Omnipod 5 in the UK and the Netherlands demonstrates Insulet’s commitment to expanding access to advanced insulin management solutions globally. Through their relentless pursuit of innovation, Insulet continues to revolutionize diabetes care and empower individuals to live life to the fullest. This latest launch further strengthens the Company’s position as a global leader in tubeless insulin pump technology.
As the prevalence of diabetes continues to rise worldwide, the availability of Omnipod 5 in the UK and the Netherlands offers new hope and improved diabetes management for thousands of individuals. With its user-friendly and reliable design, this groundbreaking insulin delivery system is set to become a game-changer in diabetes care.
In conclusion, the commercial launch of Omnipod 5, integrated with Dexcom G6 and Abbott FreeStyle Libre 2 Plus CGM sensors, ushers in a new era of insulin management in the UK and the Netherlands. This revolutionary device empowers individuals with type 1 diabetes to take control of their health, providing accurate glucose monitoring, customizable alerts, and automatic insulin delivery adjustments. With Insulet’s commitment to innovation and global expansion, Omnipod 5 is paving the way for an improved quality of life for diabetes patients around the world.
Comments